| Autor: |
Guo, Jinan, Johnson, Heather, Zhang, Xuhui, Feng, Xiaoyan, Zhang, Heqiu, Simoulis, Athanasios, Wu, Alan HB, Xia, Taolin, Li, Fei, Tan, Wanlong, Johnson, Allan, Dizeyi, Nishtman, Abrahamsson, Per‐Anders, Kenner, Lukas, Chen, Lingwu, Zhong, Wanmei, Xiao, Kefeng, Persson, Jenny L., Zou, Chang |
| Předmět: |
|
| Zdroj: |
Clinical & Translational Medicine; Mar2021, Vol. 11 Issue 3, p1-9, 9p |
| Abstrakt: |
Dear Editor, Currently no accurate prognostic test is available to predict prostate cancer (PCa) biochemical recurrence (BCR) after treatment or cancer metastasis.1-7 To address the unmet medical need, we developed a novel 23-Gene Classifier urine test as the first accurate and noninvasive tool for PCa prognosis with potential to improve cancer treatment. ROC curve of the 23-Gene Classifier (G), cancer stage (H), Gleason score (I), and combination of the 23-Gene Classifier, cancer stage and Gleason score (J) for BCR prediction in the IND-CHTN cohort. In this study, we developed and validated a novel 23-Gene Classifier that can be used as a highly accurate and noninvasive urine test for prediction of BCR and cancer metastasis with great potential to improve PCa treatment and reduce mortality in clinical practice. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
